Identification of CERS5 as a novel biomarker for prognosis and immunity in hepatocellular carcinoma: a bioinformatics analysis and functional validation study DOI Creative Commons

Peng Qiu,

Yunxiang Feng,

Kai Zhao

et al.

Research Square (Research Square), Journal Year: 2023, Volume and Issue: unknown

Published: Nov. 2, 2023

Abstract Objective Hepatocellular carcinoma (HCC) is an extremely deadly cancer with few effective therapeutic options available. Ceramide synthases (CERS), a family of enzymes that regulate sphingolipid metabolism, have been suggested to play role in initiation and progression. Whereas the specific functions CERS HCC pathogenesis not yet fully elucidated. Methods The TCGA ICGC databases were employed analyze expression levels clinical relevance genes HCC. Functional enrichment analyses performed identify pathways associated CERS5. correlation between CERS5 tumor immune microenvironment was investigated. mutation landscape immunotherapy efficacy evaluated. experiments vitro conducted assess CERS5’s impact on cell proliferation invasion. Results Aberrant detected only but also other cancers, has linked both overall survival disease-free survival. Among members, identified as prognosis-related gene, up-regulated validated database tissue samples. Higher poorer prognosis well advanced pathologic stage grade, confirmed by databases. Besides, prognostic nomogram combining stage, status, established further validated, which favorable value for prediction. showed overexpression resulted enriched carcinogenesis, drug PI3K/AKT/mTOR signaling pathway, immune-related pathways. In addition, correlated positively immunogenic death modulators checkpoints, infiltration, response, featured immunologically “hot” environment microenvironment. Finally, functional knockdown shown inhibit growth invasion hepatocellular carcinoma, potentially through targeting pathway. Conclusions Based our findings, appears great potential precise biomarker novel target

Language: Английский

Harnessing the power of traditional Chinese medicine monomers and compound prescriptions to boost cancer immunotherapy DOI Creative Commons

Keyan Miao,

Weici Liu, Jingtong Xu

et al.

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14

Published: Nov. 15, 2023

At present, cancer is the largest culprit that endangers human health. The current treatment options for mainly include surgical resection, adjuvant radiotherapy and chemotherapy, but their therapeutic effects long-term prognosis are unsatisfactory. Immunotherapy an emerging therapy has completely transformed landscape of advanced cancers, tried to occupy a place in neoadjuvant resectable tumors. However, not all patients respond immunotherapy due immunological molecular features Traditional Chinese Medicine (TCM) provides new perspective considered have potential as promising anti-tumor drugs considering its immunoregulatory properties. This review concludes commonly used TCM monomers compounds from immune regulatory pathways, aiming clearly introduce basic mechanisms boosting several common TCM. In addition, we also summarized closed ongoing trials presented prospects future development. Due significant role non-small cell lung (NSCLC), combined with should be emphasized NSCLC.

Language: Английский

Citations

21
Clinical characteristics and novel strategies of immune checkpoint inhibitor rechallenge therapy for non-small cell lung cancer: a comprehensive review DOI Creative Commons
Hao Zhang,

Yujun Hu,

Tingting Wu

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 14

Published: Jan. 12, 2024

Treatment of non-small-cell lung cancer (NSCLC) has entered the immunotherapy era, marked by significant survival improvements due to use immune checkpoint inhibitors (ICIs). However, owing factors, such as disease progression, long-term use, and side effects, some patients discontinue immunotherapy, resulting in limited subsequent treatment option a negative impact on their quality life. We have collected relevant data which reveal that ICI rechallenge may be an effective clinical strategy. many factors affect efficacy rechallenge, including patient characteristics, initial drugs, duration, efficacy, toxicity, effects. Additionally, effects mechanisms reversing drug resistance play crucial roles. Identifying suitable candidates, optimizing plans enhancing minimizing toxicity adverse rechallenges are pressing needs. Addressing these issues can provide guidance for better serve patients. This review focuses considerations strategies therapy NSCLC.

Language: Английский

Citations

4
Neoantigen immunotherapy: a novel treatment for bladder cancer DOI Creative Commons
Runxin Lv,

Zhenzhu Liu,

M. Lv

et al.

Exploration of Targeted Anti-tumor Therapy, Journal Year: 2025, Volume and Issue: 6

Published: Jan. 26, 2025

Bladder cancer is currently the most common malignant tumor of urinary system. The traditional treatment methods for bladder are mainly surgery, chemotherapy, radiotherapy, and targeted therapy; however, these do not improve clinical prognosis patients with advanced or metastatic cancer. Consequently, there an urgent need to develop new survival rate quality-of-life Over recent years, rapid development immunotherapy has become a significant alternative treatment, provides hope patients. This review aims introduce neoantigens their possible role in cancer, explore current limitations

Language: Английский

Citations

0
The efficacy of ICIs rechallenge in advanced small cell lung cancer after progression from ICIs plus chemotherapy: A real-world study DOI Creative Commons
Fen Liu,

Guisen Yin,

Ye Tao

et al.

International Immunopharmacology, Journal Year: 2025, Volume and Issue: 152, P. 114372 - 114372

Published: March 5, 2025

Language: Английский

Citations

0
Is it time to revisit the significance of PD-L1 expression in assisting our treatment decisions? DOI
Georgios Papageorgiou, Nikolaos Skouteris,

Maria Grenzelia

et al.

Immunotherapy, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 5

Published: March 21, 2025

Language: Английский

Citations

0
Rare, late onset of immune checkpoint inhibitor-induced type 1 diabetes mellitus in a patient with small-cell lung cancer treated with serplulimab: a case report and review of the literature DOI Creative Commons
Peng Ning,

Shilan Liu,

Hongyi Cao

et al.

Journal of Medical Case Reports, Journal Year: 2024, Volume and Issue: 18(1)

Published: Jan. 22, 2024

Abstract Background As a newly approved immune checkpoint inhibitor in China, serplulimab has been widely used the immunotherapy of tumors. However, immune-related adverse events inhibitors should not be ignored. Although inhibitor-induced type 1 diabetes mellitus is rare complication, it may cause diabetic ketoacidosis and endanger lives patients. Case presentation This case report describes 55-year-old male Han nationality from China diagnosed with small-cell lung cancer multiple metastases who experienced an event 68 weeks after receiving therapy. The patient presented typical symptoms ketoacidosis, including severe thirst, nausea, vomiting, deep respirations, stupor. Despite absence diabetes-related autoantibodies, had extremely low levels insulin C-peptide release. Other potential causes were ruled out, confirming condition as serplulimab-induced mellitus. After aggressive treatment to correct patient’s blood glucose stabilized improved significantly, although long-term maintenance therapy was necessary. Conclusion highlights rare, late-onset that overlooked during serplulimab. monitoring early signs cannot relaxed at late stage treatment, even if patients do have elevated before middle treatment.

Language: Английский

Citations

3
EGFR-Tyrosine Kinase Inhibitor Retreatment in Non-Small-Cell Lung Cancer Patients Previously Exposed to EGFR-TKI: A Systematic Review and Meta-Analysis DOI Open Access
Isabella Michelon, Maysa Vilbert,

Caio Ernesto do Rego Castro

et al.

Journal of Personalized Medicine, Journal Year: 2024, Volume and Issue: 14(7), P. 752 - 752

Published: July 15, 2024

We performed a systematic review and meta-analysis to assess the efficacy of EGFR-tyrosine kinase inhibitors (TKI) retreatment in advanced/metastatic non-small-cell lung cancer (NSCLC) patients. systematically searched PubMed, Embase, Cochrane databases, ASCO, ESMO websites for studies evaluating EGFR-TKI NSCLC All analyses were using R software (v.4.2.2). included 19 (9 CTs 10 retrospective cohorts) with total 886 In pooled analysis all patients during TKI, median OS was 11.7 months (95% confidence interval [CI] 10.2–13.4 months) PFS 3.2 CI 2.5–3.9 months). ORR 15% 10–21%) DCR 61% 53–67%). The subanalysis by generation TKI rechallenge period revealed slightly better on 3rd (p = 0.05). Some limitations include high heterogeneity some inability perform certain subanalyses. Our results unequivocally support benefit EGFR-mutated progressing treatment after TKI-free interval. These findings may be especially valuable areas where access novel therapeutic drugs clinical trials is limited.

Language: Английский

Citations

2
Single Institution Experience with Immune Checkpoint Inhibitors in Vulvar and Vaginal Melanomas DOI Creative Commons

Amrita Ladwa,

Omar Elghawy, Varinder Kaur

et al.

Obstetrics and Gynecology International, Journal Year: 2024, Volume and Issue: 2024(1)

Published: Jan. 1, 2024

This study aimed to report clinical outcomes of patients with vaginal melanoma (VaM) or vulvar (VuM) who were treated immune checkpoint inhibitors (ICI) and discuss the development immune-related adverse events (irAE).

Language: Английский

Citations

2
Extensive Stage Small-Cell Lung Cancer with Cystic Brain Metastases: A Report of Two Cases DOI Creative Commons
Fei Cai, Di Wu, Junling Liu

et al.

Cancer Management and Research, Journal Year: 2024, Volume and Issue: Volume 16, P. 177 - 183

Published: March 1, 2024

Objective: Cystic brain metastases (BMs) are rare in small cell lung cancer (SCLC), and there limited data on the treatment prognosis of cystic BMs. Whole radiotherapy has been mainstay for BMs since several years. Immune checkpoint inhibitors extensive stage (ES-SCLC) have shown to be suitable patients who experienced better overall survival progress-free approved as first-line ES-SCLC. In this report, we described two ES-SCLC developed after immunotherapy, which continued treat primary lesion with immune radiotherapy. Case Description: Two male were diagnosed at first admission subsequently treated immunotherapy plus platinum therapy, during developed. One patient received whole other Gamma knife radiosurgery (GKRS). Immunotherapy was lesions controlled. It 33 months is now stable condition. The achieved an 30 months. Conclusion: This report describes a good effect local control can significantly improve symptoms patients. At same time, treatment, then perform cross-immunotherapy disease progression, combined anti-vascular targeting drugs. did not develop severe iRAEs. Keywords: ES-SCLC, BMs, cross-line

Language: Английский

Citations

1
Effective control of postoperative recurrence of pregnancy-related gastric cancer using anti-PD-1 as a monotherapy: a case report DOI Creative Commons
Xu Liu, Xiaoqi Li, Chunchao Zhu

et al.

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: May 10, 2024

Pregnancy-related gastric cancer is characterized by a refractory nature and poor prognosis; few cases during pregnancy achieved acceptable outcomes using anti-PD-1 as monotherapy. A 32-year-old pregnant female patient was admitted to the emergency department of obstetrics gynecology eventually diagnosed with cancer. Radical surgery for conducted after termination pregnancy. At 1-year postoperative follow-up, tumor recurrence revealed. This has decrease in burden receiving case documents response PD-1 monotherapy pregnancy-related highlights potential future use specific clinical scenarios.

Language: Английский

Citations

1